Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?

International Journal of Biological Markers

Volumn 15, Issue 2, 2000, Pages 135-138

  Floiras, J L ^c   Hacene, K ^c   Turpin, F ^c   Spyratos, F ^a,b  

^a CENTRE RENÉ HUGUENIN   (France)

^b Center René Huguenin   (France)

^c NONE

Author keywords

Breast cancer; Estrogen receptors; Post menopause; Tamoxifen

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE;

EID: 0034125714     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080001500202     Document Type: Article

References (7)

1. Osborne CK, Elledge RM, Fuqua SAW. Estrogen receptors in breast cancer therapy. Sci Am Sci Med 1996; 3: 32-41.
2. Elledge ME, Osborne CK. Oestrogen receptors and breast cancer. BMJ 1997; 314: 1843-44.
3. Heuson JC, Longeval E, Mattheiem WH, Deboel MC, Sylvester RJ, Leclercq G. Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer 1977; 39: 1971-7.
4. Thorpe SM, Christensen IBJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer 1993; 29A: 971-7.
5. Sancho-Garnier H, Delarue JC, Mouriesse H, et al. Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? Eur J Cancer 1995; 31A(11): 1851-5.
6. Early Breast Cancer Trialists' Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-67.
7. Allred DC, Harvey JM, Berardo M, Clark G. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11(2): 155-68.